Browse

Crizotinib versus chemotherapy in asian patients with alk-positive advanced non-small cell lung cancer

Cited 17 time in Web of Science Cited 21 time in Scopus
Authors
Nishio, Makoto; Kim, Dong-Wan; Wu, Yi-Long; Nakagawa, Kazuhiko; Solomon, Benjamin J.; Shaw, Alice T.; Hashigaki, Satoshi; Ohki, Emiko; Usari, Tiziana; Paolini, Jolanda; Polli, Anna; Wilner, Keith D.; Mok, Tony
Issue Date
2018-07
Citation
Cancer Research and Treatment, Vol.50 No.3, pp.691-700
Keywords
AsiaCarboplatinCisplatinCrizotinibNon-small cell lung carcinomaPemetrexed
Abstract
Purpose Crizotinib has demonstrated superior progression-free survival (PFS) and objective response rates (ORRs) versus chemotherapy in previously treated and untreated patients with anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC). We report the safety and efficacy of crizotinib in Asian subpopulations of two global phase III trials. Materials and Methods This analysis evaluated previously treated and untreated patients in two randomized, open-label phase III trials of crizotinib versus chemotherapy in ALK-positive advanced NSCLC in second-line (PROFILE 1007) and first-line settings (PROFILE 1014). Efficacy and safety were analyzed by race in the intention-to-treat and "as-treated" populations for efficacy and safety endpoints, respectively. Results In previously treated (n=157) and untreated (n=157) Asian patients, PFS was statistically significantly longer with crizotinib versus chemotherapy (hazard ratio for PFS, 0.526; 95% confidence interval, 0.363 to 0.762; p < 0.001 and hazard ratio, 0.442; 95% confidence interval, 0.302 to 0.648; p < 0.001, respectively). Similar antitumor activity was seen in the non-Asian and overall populations. ORRs were statistically significantly higher with crizotinib versus chemotherapy in both Asian and non-Asian previously treated and untreated patients (p < 0.05). The most common treatment-emergent adverse events (any grade) with crizotinib were vision disorder, diarrhea, and nausea, which were observed at a comparable incidence across Asian and non-Asian populations, irrespective of previous treatment status. Most adverse events were mild to moderate in severity. Conclusion These data, currently the only analysis showing Asian and non-Asian populations in the same study, support the efficacy and safety of crizotinib in Asian patients with previously treated or untreated ALK-positive advanced NSCLC.
ISSN
1598-2998
URI
https://hdl.handle.net/10371/165225
DOI
https://doi.org/10.4143/crt.2017.280
Files in This Item:
Appears in Collections:
College of Medicine/School of Medicine (의과대학/대학원)Cancer Research Institute (암연구소)Journal Papers (저널논문_암연구소)
College of Medicine/School of Medicine (의과대학/대학원)Internal Medicine (내과학전공)Journal Papers (저널논문_내과학전공)
  • mendeley

Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse